高级检索
徐园园, 李小杉, 吴苏姝, 刘黎, 郭璐, 李昕, 朱正平. 南京市2004 — 2016年接受抗病毒治疗HIV/AIDS患者生存分析[J]. 中国公共卫生, 2018, 34(4): 473-478. DOI: 10.11847/zgggws1116546
引用本文: 徐园园, 李小杉, 吴苏姝, 刘黎, 郭璐, 李昕, 朱正平. 南京市2004 — 2016年接受抗病毒治疗HIV/AIDS患者生存分析[J]. 中国公共卫生, 2018, 34(4): 473-478. DOI: 10.11847/zgggws1116546
Yuan-yuan XU, Xiao-shan LI, Su-shu WU, . Survival of HIV/AIDS patients receiving highly antiretroviral therapy in Nanjing city, 2004 – 2016[J]. Chinese Journal of Public Health, 2018, 34(4): 473-478. DOI: 10.11847/zgggws1116546
Citation: Yuan-yuan XU, Xiao-shan LI, Su-shu WU, . Survival of HIV/AIDS patients receiving highly antiretroviral therapy in Nanjing city, 2004 – 2016[J]. Chinese Journal of Public Health, 2018, 34(4): 473-478. DOI: 10.11847/zgggws1116546

南京市2004 — 2016年接受抗病毒治疗HIV/AIDS患者生存分析

Survival of HIV/AIDS patients receiving highly antiretroviral therapy in Nanjing city, 2004 – 2016

  • 摘要:
      目的  了解南京市2004 — 2016年首次接受抗病毒治疗的艾滋病病毒感染者/艾滋病患者(HIV/AIDS)生存情况,并探索影响患者死亡的危险因素。
      方法  采用回顾性队列研究方法对南京市2004 — 2016年 ≥ 15岁、首次接受抗病毒治疗患者的数据进行生存分析,采用寿命表法计算生存率,采用Cox比例风险模型分析影响死亡的危险因素。
      结果  纳入本研究的2 523例研究对象开始抗病毒治疗时的年龄中位数为32(IQR = 26~44)岁,从确诊HIV抗体阳性到开始抗病毒治疗的时间中位数为2(IQR = 1~8)月,以男性、本地户籍、未婚、体质指数(BMI)为18.5~23.9 kg/m2组、同性性传播、基线CD4+T淋巴细胞(CD4)计数 ≤ 200个/μL、WHO临床Ⅰ期、初始治疗方案TDF + 3TC + EFV/NVP为主。随访期间因艾滋病相关疾病死亡70例,病死率为1.49/100人年(85.96/5 777.69)。抗病毒治疗后第1、2、5、7、12年的累积生存率分别为98.01 %、96.93 %、95.20 %、94.30 %和92.76 %。多因素Cox比例风险模型分析结果显示:≥ 50岁年龄组(HR = 11.31,95 %CI = 2.62~48.87),基线有 ≥ 4个症状/体征(HR = 2.98,95 % CI = 1.37~6.50)的抗病毒治疗患者死亡风险较高;同性性传播(HR = 0.29,95 % CI = 0.10~0.87),BMI 24~kg/m2HR = 0.06,95 % CI = 0.01~0.27),基线CD4计数351~500 个/μL(HR = 0.23,95 % CI = 0.07~0.76)是患者死亡的保护因素。
      结论  南京市HIV/AIDS抗病治疗累积生存率较高,开始治疗时年龄 ≥ 50岁、出现艾滋病相关症状/体征、BMI较低、基线CD4计数较低的HIV/AIDS死亡风险较高。

     

    Abstract:
      Objective  To examine the survival status of human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) patients initially receiving highly antiretroviral therapy (HAART) and to explore associated factors with HIV-related death in Nanjing city during 2004 – 2016.
      Method  A retrospective cohort study was conducted to analyze the data on HIV/AIDS patients over 15 years old initially receiving HAART in Nanjing city during 2004 – 2016. Life table method was adopted to estimate survival rates and the Cox proportion hazard model was used to analyze predictors of HIV-related death.
      Results  Among the 2 523 participants, the median age when starting HAART was 32 years (interquartile range IQR: 26 – 44) and the median time from the diagnosis of HIV positive to the beginning of HAART was two months (IQR: 1 – 8 months). OF the participants, 93.26% were males; 85.93% were locally registered residents; and 50.65% were unmarried. The body mass index (BMI) ranged from 18.5 to 23.9 kg/m2 among 63.69% of the participants. HIV infection via homosexual transmission was ascertained for 73.17% of the participants. The baseline mean of CD4+T cell count was 271 cells/μL for all the participants. The initial therapeutic regimen was tenofovir plus lamivudine plus efavirenz or nevirapine (TDF+3TC+EFV/NVP) for 50.81% of the participants and 47.9% of the participants were at the first clinical stage based on World Health Organization (WHO) category when receiving the initial treatment. During the follow-up period, a total of 70 cases died of HIV-related diseases and the mortality was 1.49/100 (85.96/5 777.69) person years. The cumulative survival rate of the participants was 98.01%, 96.93%, 95.20%, 94.30%, and 92.76% after 1, 2, 5, 7, and 12 years of HAART, respectively. Multivariate Cox proportion hazard models revealed that the participants with following characteristics were at higher mortality risk: aged ≥ 50 years (hazard risk HR = 11.31, 95% confidence interval 95% CI: 2.62 – 48.87), with 4 or more signs/symptoms of AIDS at the baseline examination (HR = 2.98, 95% CI: 1.37 – 6.50); whereas the participants being infected via homosexual transmission (HR = 0.29, 95% CI: 0.10 – 0.87), with the body mass index (BMI) of ≥ 24 kg/m2 (HR = 0.06, 95% CI: 0.01 – 0.27), and with CD4+T cell count of ≥ 350 cells/μL at the baseline examination (HR = 0.23, 95% CI: 0.07 – 0.76) were at lower mortality risk.
      Conclusion  The cumulative survival rate is higher among HAART-treated HIV/AIDS patients in Nanjing city but the patients over 50 years old, with signs/symptoms of AIDS, lower BMI, and lower CD4+T cell count are at a higher mortality risk.

     

/

返回文章
返回